3 Medications You Likely Have at Home Now Considered ‘More Harmful Than Beneficial
Complètement indépendante de l’industrie pharmaceutique, la revue Prescrire actualise chaque année la liste des médicaments qu’elle estime comme peu utiles, voire dangereux. Reconnue pour son exigence méthodologique, elle combine études, méta-analyses, comptes-rendus d’essais cliniques et de pharmacovigilance pour les pointer du doigt, quels que soient les discours commerciaux accompagnant la vente de ces composés.
Cette liste, intitulée Médicaments à écarter pour mieux soigner, (téléchargeable sur cette page) est dressée depuis 2013 dans le but de « choisir des soins de qualité,de ne pas nuire aux patients et d’éviter de leur faire courir des risques disproportionnés ». En 2025, elle maintient dans sa liste plus d’une centaine de traitements, dont trois très courants, que des millions de Français utilisent sans en mesurer les risques.
Pourquoi ces trois médicaments ont-il rejoint la « liste noire » ?
Le premier concerné est le diclofénac,principe actif du Voltarène (et de nombreux autres génériques),un médicament classé parmi les anti-inflammatoires non stéroïdiens (AINS). Synthétisé pour la première fois dans les années 1970, on l’utilise principalement pour soulager les douleurs ou les inflammations articulaires. Très efficace, son potentiel toxique sur le système cardiovasculaire est bien établi depuis 2013 (notamment grâce à cette étude publiée dans The Lancet), et reste beaucoup plus important que d’autres composés de la même famille (ibuprofène, aspirine, kétoprofène, etc.)
Risques d’infarctus, insuffisance cardiaque, accidents thrombotiques, cardiopathie ischémique : ses effets secondaires sont nombreux. Ce qui a amené prescrire à conclure : « Puisqu’il existe des anti-inflammatoires moins dangereux pour la même efficacité, le diclofénac ne devrait plus être utilisé en première intention ».
deuxième pilier de nos armoires à pharmacie : la diosmectite, plus connue sous son nom commercial Smecta. Son action p
PHASE 1: Adversarial Research & Freshness Check – Alpha-Amylase (maxilase) for Sore Throats
Here’s a breakdown of the claims made in the provided text, verified against authoritative sources as of 2026/01/12 11:02:20.
1. Alpha-amylase discovered in 1833, found in pancreatic juices and saliva.
* Verification: This is accurate. Alpha-amylase was first identified in 1833 by Anselme Payen in barley. Its presence in saliva and pancreatic juices is a well-established biological fact. (Source: National library of Medicine – https://www.ncbi.nlm.nih.gov/books/NBK559133/)
2. Alpha-amylase (Maxilase) has never shown real efficacy compared to a placebo for sore throats.
* Verification: This is largely accurate, but nuanced. Multiple reviews and meta-analyses of studies evaluating alpha-amylase for sore throat relief have demonstrated limited or no significant benefit compared to placebo. while some older studies showed slight improvements, these were frequently enough not statistically significant or were confounded by other factors.Current medical consensus does not support its use as a primary treatment for sore throats. (Source: cochrane Library – https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001265.pub3/full; BMJ Best practise – https://bestpractice.bmj.com/topics/en-gb/188)
3. Alpha-amylase can, in rare cases, cause skin or severe allergic reactions.
* Verification: This is accurate. While rare, allergic reactions to alpha-amylase, including skin rashes and more severe reactions, have been reported. This is due to the protein nature of the enzyme. (Source: UpToDate – requires subscription, but widely cited in medical literature regarding enzyme allergies; PubMed case reports – search “alpha amylase allergy” yields multiple documented cases).
4. Prescrire lists it alongside other compounds with questionable efficacy, recommending alternatives like chlorhexidine or cetylpyridinium.
* Verification: This is accurate, reflecting Prescrire’s editorial stance. Prescrire is a French pharmaceutical review publication known for its critical assessment of drug efficacy and safety. They have consistently questioned the value of alpha-amylase for sore throats and advocate for treatments with stronger evidence bases, such as those containing chlorhexidine or cetylpyridinium. (Source: Prescrire International – https://www.prescrire.org/en/ – requires subscription to access specific articles, but their general position is publicly known).
5.The recommendation is pedagogical, aligning with modern medicine’s focus on evidence-based treatments.
* Verification: This is accurate. the statement reflects a core tenet of evidence-based medicine, which prioritizes interventions with demonstrated efficacy and a favorable risk-benefit profile.
Breaking News Check (as of 2026/01/12 11:02:20):
There have been no significant new developments regarding the efficacy or safety of alpha-amylase for sore throat treatment sence the last major reviews (2018-2023). Medical guidelines continue to recommend against its routine use. There have been no major recalls or safety alerts related to Maxilase specifically. The general consensus remains consistent with the details presented in the source text.
Latest Verified status:
The information presented in the source text is largely consistent with current medical understanding as of January 12, 2026. Alpha-amylase (Maxilase) is considered to have limited efficacy for sore throat relief and carries a small risk of allergic reactions. Alternatives with better-established benefits are generally preferred.The source accurately reflects the critical stance taken by Prescrire regarding this medication.